|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
B-raf V600E protein analysis revealed a subjacent layer of heterogeneity for mutation-positive metastatic melanomas.
|
31835364 |
2019 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Targeted therapies, based on identification of common oncogenic mutations such as BRAF V600E/K and monoclonal antibody immunotherapies, have transformed the treatment of melanoma.
|
30868471 |
2019 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Notorious oncogenic BRAF V600E plays a significant role in the signal transduction of the MAPK pathway, which is involved in tumor growth, especially in melanoma.
|
30630714 |
2019 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Patients with rare <i>BRAF</i> mutations can respond to targeted therapy, however, efficacy seems to be lower compared with V600E mutated melanoma.
|
31580757 |
2019 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
<b>:</b> The introduction of v-raf murine sarcoma viral oncogene homolog B (BRAF) inhibitors in melanoma patients with BRAF (V600E) mutations has demonstrated significant clinical benefits.
|
31416288 |
2019 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
To anticipate possible resistance to ERK inhibitors (ERKi), we used SCH772984 (SCH) as a model ERKi to characterize resistance mechanisms in two BRAF V600E melanoma cell lines.
|
30833419 |
2019 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Only one case of urethral melanoma showed a BRAF non-V600E mutation (D594G).
|
31567539 |
2019 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The combination of a BRAF inhibitor dabrafenib and a MEK inhibitor trametinib (CombiDT) has improved outcomes compared with chemotherapy or BRAF inhibitor monotherapy in advanced BRAF V600E/K melanoma.
|
30661097 |
2019 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Here, we tested the BETi, PLX51107, for immune-based effects on tumor growth in BRAF V600E melanoma syngeneic models.
|
31063649 |
2019 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Correlative preclinical studies demonstrated broad activity for E6201 across BRAF V600E mutant melanoma cell lines and effective BBB penetration in vivo.
|
30264293 |
2019 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Our results demonstrated that the BRAF V600E mutation is a frequent event in Indian melanomas, and represents an important molecular target for novel therapeutic approaches.
|
30803557 |
2019 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Orthogonal partial least squares (O-PLS) predicted vemurafenib sensitivity with greater accuracy in both melanoma and non-melanoma BRAF-V600E cell lines than other leading machine learning methods, specifically Random Forests, Support Vector Regression (linear and quadratic kernels) and LASSO-penalized regression.
|
31672130 |
2019 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Specific mutations of RAF kinases, such as the prevalent BRAF(V600E) mutation in melanoma, or defects in upstream signaling or feedback loops cause decoupled kinase activities which lead to tumorigenesis.
|
28466200 |
2019 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
CTC profiling was performed using 5 known melanoma mRNA biomarkers and BRAF V600E DNA mutation.
|
31672856 |
2019 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The US Food and Drug Administration approved a liquid biopsy test for EGFR-activating mutations in patients with non-small-cell lung cancer as a companion diagnostic for therapy selection. ctDNA also allows for the identification of mutations selected by treatment such as EGFR T790M in non-small-cell lung cancer. ctDNA can also detect mutations such as KRAS G12V in colorectal cancer and BRAF V600E/V600K in melanoma.
|
30883505 |
2019 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
This study thus defined SPRY4 as a potential mediator of synthetic suppression, which is likely to contribute to the observed exclusivity between BRAF(V600E) and NRAS(Q61R) mutations in melanoma.
|
30651601 |
2019 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Patients with BRAF V600E-mutated melanoma respond to FDA-approved BRAF inhibitors.
|
29271794 |
2019 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
AHR activation induces the expression of resistance genes against the inhibitors of V600E mutated B-Raf proto-oncogene, serine/threonine kinase (BRAF) in melanoma and upregulation of programmed cell death protein 1 (PD-1) in tumor-infiltrating T cells surrounding melanoma.
|
31552251 |
2019 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
BRAF inhibitors (BRAFi) are used to treat patients with melanoma harboring the V600E mutation.
|
30482853 |
2019 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The presence of a BRAF V600E mutation and activation of ERK, MEK, S6, and AKT were assessed with immunohistochemistry in 35 conjunctival nevi and 31 melanomas.
|
31247083 |
2019 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The present study aims to assess the prevalence and prognostic significance of BRAF V600E mutation and apprehend its association with clinicopathologic features in stage I to III Turkish melanoma patients.
|
31058533 |
2019 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Here we assessed the role of urokinase type plasminogen activator receptor (uPAR) as a potentially valuable biomarker in the acquisition of BRAF-I resistance in V600E mutant melanoma cells.
|
30611716 |
2019 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
A PDOX nude mouse model of a BRAF V600E-mutant melanoma was established in the chest wall of nude mice and also tested with rMETase in combination with a first-line melanoma drug, temozolomide (TEM).
|
30725414 |
2019 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Importantly, ERK1/2 inhibition may have clinical utility in overcoming acquired resistance to RAF and MEK inhibitors, where RAS/MAPK pathway reactivation has occurred, such as relapsed BRAF V600E/K melanoma.
|
31710489 |
2019 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Sixty five consecutive formalin-fixed paraffin-embedded (FFPE) melanoma samples were prospectively tested for BRAF mutations with the VE1 (anti-BRAF V600E) antibody and for both BRAF and NRAS mutations with the Idylla NRAS-BRAF-EGFR S492R Mutation Assay cartridges.
|
31415669 |
2019 |